NNG NanoGroup S.A.

GPW · PL · Healthcare · Biotechnology · nanogroup.eu

2.430PLN-1.62%Mkt Cap: 26.23M $P/E: —Today

NanoGroup S.A. operates as a biotechnology company in Poland. It engages in the production of medicines and other pharmaceutical products, and research and development work in the field of biotechnology and other natural…

Industry Peers

Biotechnology

Screen all

VRTX

Vertex Pharmaceuticals Incorporated - Common Stock

$127.85BUSDP/E 29.4

MRNA

Moderna, Inc. - Common Stock

$75.86BUSD

REGN

Regeneron Pharmaceuticals, Inc. - Common Stock

$75.69BUSDP/E 18.2

ARGX

argenx SE - American Depositary Shares

Revolution Medicines, Inc. - Common Stock

BeOne Medicines Ltd. - American Depositary Shares

$40.51BUSDP/E 63.9

RPRX

Royalty Pharma plc - Class A Ordinary Shares

$33.03BUSDP/E 30.7

ALNY

Alnylam Pharmaceuticals, Inc. - Common Stock

$29.40BUSDP/E 38.3

ROIV

Roivant Sciences Ltd. - Common Shares

$25.80BUSD

BNTX

BioNTech SE - American Depositary Shares

$24.34BUSD

INSM

Insmed Incorporated - Common Stock

$24.27BUSD

INCY

Incyte Corporation - Common Stock

Genmab A/S - American Depositary Shares

$21.69BUSDP/E 27.4

JAZZ

Jazz Pharmaceuticals plc - Ordinary Shares

$15.30BUSDP/E 16.1

ASND

Ascendis Pharma A/S - Ordinary Share

$14.99BUSDP/E 17.8

EXEL

Exelixis, Inc. - Common Stock

$14.47BUSDP/E 18.4

SMMT

Summit Therapeutics Inc. - Common Stock

$13.37BUSD

Key Statistics

Company

Market Cap26.23M USD

Enterprise Value24.74M USD

Revenue (TTM)732.68K USD

Gross Profit-93.80K USD

Net Income (TTM)-2.39M USD

Revenue/Share—

Last Price2.430 PLN

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees—

CountryPL

SectorHealthcare

IndustryBiotechnology

ISINPLNNGRP00011

Valuation

P/E (Trailing)—

P/E (Forward)—

PEG—

EV/EBITDA-8.47

EV/Revenue33.76

P/S36.40

P/B3.40

EPS (TTM)-0.23

EPS (Forward)—

52W Range

2.17525% of range3.200

52W High3.200 PLN

52W Low2.175 PLN

Profitability

Gross Margin21.49%

Oper. Margin-144.76%

EBITDA Margin0.00%

Profit Margin0.00%

ROE-108.69%

ROA-23.29%

Growth

Revenue Growth1819.50%

Earnings Growth—

Cash Flow & Leverage

Operating CF-2.23M USD

CapEx (TTM)3.74M USD

FCF Margin-340.16%

FCF Yield-9.50%

Net Debt-2.04M USD

Net Debt/EBITDA0.70

Balance Sheet

Debt/Equity0.00

Current Ratio8.26

Quick Ratio7.44

Book Value/Sh0.73 PLN

Cash/Share0.19 PLN

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 PLN

Div. Yield0.00%

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating—

Target (Mean)—

Target Range—

# Analysts—

Ownership

Shares Out.42.63M

Float25.27M

Insiders30.12%

Institutions1.64%

Technical

SMA 502.458 (-1.1%)

SMA 2002.493 (-2.5%)

Beta—

S&P 52W Chg14.58%

Avg Vol (30d)43.79K

Avg Vol (10d)34.67K

Technical Indicators

RSI (14)49.9

MACD0.0060

MACD Signal0.0078

MACD Hist.-0.0018

BB Upper2.552 PLN

BB Middle2.479 PLN

BB Lower2.407 PLN

BB Width5.81%

ATR (14)0.0688 PLN

Vol Ratio (20d)0.18x